Cardiff University MDI-26478 drug is a potential new treatment for schizophrenia developed by the Medicines Discovery Institute (MDI) at the university.
Our scientists worked with their colleagues at the MDI to design a three-part First in Human study. This required us to collaborate with both the Cardiff University Brain Research Imaging Centre (CUBRIC) for neuroimaging and cognitive assessments, as well as niche CRO, The Science Behind who performed the EEG assessments and collected CSF samples in our Clinical Pharmacology Unit.